RxDoctor Payments Data

Amanda Moroz

Psychiatric/Mental Health · Neptune, NJNPI 1043832520

Payments from drug & device makers

$3,806in general payments, 2019–2025

Across 260 payments — averaging $14.64 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$1K
  • Alkermes, Inc.$457
  • ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$424
  • Otsuka America Pharmaceutical, Inc.$299
  • Neurocrine Biosciences, Inc.$216
  • Lundbeck LLC$184
  • plus $1K from 16 others

What the payments were for

  • Food & beverage$3,806100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$3,806 in reported general payments places this provider in the 90th percentile of 1,212 psychiatric/mental health providers in New Jersey.

See all psychiatric/mental health providers in New Jersey

Medicare billing

Part B allowed, 2024
$45,132
Medicare patients
36
Services billed
580

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
RexultiBrexpiprazole21$30,253
SpravatoEsketamine Hcl21$21,518
Aripiprazole45$1,412
Desvenlafaxine Succinate ErDesvenlafaxine Succinate27$1,120
Quetiapine Fumarate40$980
Dextroamphetamine-AmphetamineDextroamphetamine/Amphetamine25$738
Bupropion XlBupropion Hcl32$701
Oxcarbazepine15$648
Thioridazine Hcl11$441
Venlafaxine Hcl ErVenlafaxine Hcl32$421
Haloperidol35$412
Fluoxetine Hcl23$267
Clonazepam26$209
Mirtazapine17$200
Sertraline Hcl50$184

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Otsuka America Pharmaceutical, Inc.Rexulti$299$30,25321 claims
Johnson & JohnsonSpravato$86$21,51821 claims
Almatica Pharma LLCSertraline Hcl$60$18450 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 1,212 psychiatric/mental health providers in New Jersey.

Other psychiatric/mental health in Neptune

See the full list for New Jersey

Where these figures come from

Is this you, or does something look wrong? →